Abstract There is increasing support for the hypothesis that most tumors contain a subpopulation of cells, referred to here as tumor initiating cells (TICs), with the ability to self-renew and to regenerate all the cell types within the tumor. TICs are enriched in breast cancer patients after common treatments, indicating their intrinsic therapeutic resistance. Two independently-derived gene transcription "signatures" of TICs from different studies indicate enrichment of TICs within the recently-identified "claudin-low" intrinsic molecular subtype of breast cancer. These are characterized by high expression of markers associated with epithelial-mesenchymal transition (EMT), suggesting that claudin-low cells may arise from more immature stem or progenitor cells than other breast cancers. EMT is a process by which cells acquire molecular alterations that facilitate dysfunctional cell-cell adhesive interactions and junctions, as well as a more spindle-shaped morphology. These processes may promote cancer cell progression and invasion into the surrounding microenvironment. Induction of EMT in immortalized human mammary epithelial cells results in an increased ability to form mammospheres, and in the expression of stem cell and TIC markers, suggesting that there may be a direct link between the EMT and the gain of TIC properties. Targeting specific molecular pathways-such as Notch, Wnt, and TGFß-associated with development and EMT in the TIC subpopulation, in addition to conventional chemo-and radiation therapies that target the bulk tumor, may ultimately provide a more effective strategy in treating breast cancer. Here, we review recent evidence of the involvement of EMT in breast cancer TICs, focusing on clinical studies.
Introduction
Breast cancer is not a single disease, but is instead a collection of diseases displaying distinct histopathological features, genetic and genomic variability, and diverse prognostic outcomes [1, 2] . Notwithstanding recent improvements in mortality in breast cancer patients, many patients relapse despite an initial response to conventional endocrine and chemotherapies. Several alternative but not necessarily mutually exclusive hypotheses have been proposed to explain treatment failure and recurrence. For example, the residual tumor cells not eliminated by initial therapy may develop acquired resistance, due to a number of mechanisms including increased drug efflux, metabolism and mutations of specific targets. Alternatively, it has been suggested that there may be a subpopulation of cells within tumors that show stem cell characteristics, and which may possess an intrinsic resistance to endocrine and chemotherapy [3] . This population is also thought to be the Tumor Initiating Cells (TICs), which can be isolated by flow cytometry techniques using specific cell surface markers [4] .
Recently, we provided clinical evidence that TICs are enriched in breast cancer patients after common treatments, indicating intrinsic therapeutic resistance of the tumorigenic subpopulation of cells [5] . Our analysis of the gene expression patterns of these TICs has implicated pathways involved in epithelial-mesenchymal transition (EMT) [6] , which would be in line with the results of other recent studies. Here, we review recent studies of TICs and the involvement of EMT in breast cancer, and what implications this connection might have for our ability to more effectively treat this disease. We also evaluate a number of recently published gene transcription signatures of TICs, for their patterns of enrichment both within the "claudinlow" breast cancer molecular subtype and within cancers after therapy treatment.
The Tumor-Initiating Cell (TIC) Hypothesis
Increasing evidence, both from model systems and recent clinical studies, support the hypothesis that most tumors contain a minor subpopulation of cells with distinct properties similar to somatic stem cells. Like normal stem cells, these cells have the ability to self-renew and to regenerate all the cell types within the tumor mass. These cells have been referred to as cancer stem cells or tumor initiating cells (TICs). This is an old hypothesis, but the field has recently exploded, initially with the discovery that the cell capable of initiating human acute myeloid leukemia (AML), the leukemia-initiating cell, possessed the potential for self-renewal and differentiation expected of a leukemia stem cell. This was shown using cell surface markers and transplantation into non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice) [7] . Similar approaches have now been adapted for identifying tumor initiating cells in many solid human cancers including colon, brain, and breast [4, 8, 9] .
TICs can be isolated by fluorescence-activated cell sorting (FACS), using specific cell surface and other markers from the bulk of the tumor cells. For example, Al-Hajj showed, in a seminal study that isolated cells from metastatic pleural effusions from breast cancer, that the CD44 + /24 -/low /lineage -subpopulation was enriched for TICs [4] . The formation of mammospheres, threedimensional clusters of cells which can self-renew and grow in an anchorage-independent manner, is thought to represent another hallmark of TICs. Studies by Dontu et al. [10] [11] [12] showed that normal mammary stem cells undergo primarily asymmetric self-renewal to form mammospheres, whereas the differentiated cells undergo apoptosis. Malignant TICs behave similarly, though with an even higher propensity for symmetric self-renewal.
Of clinical significance, it has been shown that TICs may have an intrinsic resistance to therapy [5, 13, 14] . Therefore, current treatment strategies may affect the bulk of the tumor cells, but leave TICs behind, serving as a reservoir for disease recurrence. Analogous to the propensity of dandelion roots to regenerate weeds, regrowth of tumors from an intrinsically therapy-resistant subpopulation has been termed the "dandelion hypothesis" [15] . If this hypothesis is true, then an understanding of the mechanisms responsible for this intrinsic resistance and the development of new therapies to target TICs in conjunction with currently used conventional treatments would be of critical importance to improve overall patient survival.
TICs in Human Breast Cancers
The hypothesis that TICs are intrinsically resistant to therapy was supported by a recent study from our group [5] , in which we found breast cancers after chemotherapy to have higher levels of CD44 + /CD24
-/low (a marker of TICs). In the study, paired tumor core biopsies were taken from patients with primary breast cancer before and after 12 weeks of treatment with neoadjuvant chemotherapy or, for patients with HER2-positive tumors, before and after 6 weeks of treatment with the EGFR/HER2 inhibitor lapatinib. The cells were assayed for the percentage of CD44 + /CD24
-/low cells and the ability to form mammospheres in vitro as an indication of self-renewal. The cancers after chemotherapy had a greater percentage of TICs and a greater propensity to form mammospheres. On the other hand, lapatinib treatment did not increase the proportion of TICs in HER2-positive breast cancers, which suggests that the TICs in these cancers may be targeted by anti-HER2 therapy.
As the above study indicates, the percentage of TICs may vary from tumor to tumor; one may ask the question as to whether this percentage varies by molecular subtype. Gene expression profiling of human breast tumors has been used to classify them into several distinct and clinically relevant groups (basal-like, luminal A, luminal B, HER2+/ ER-, and normal-like) [2, 16] . Recently, a new and rare molecular subtype of human breast cancer, referred to as the "claudin-low" group, was identified in a study by Herschkowitz et al. [17] , in which a larger number of breast tumors were profiled than had been in the earlier seminal studies that first defined the other molecular subtypes. As these claudin-low tumors appear to only represent less than 5% of breast cancers, this would explain why they had been missed previously. Like basal-like tumors, claudin-low tumors are generally triple negative (ER-, PR-, HER2-); however, they uniquely express low levels of tight and adherens junction genes including Claudin 3 and Ecadherin. While named for the claudin family, there are many other genes that characterize claudin-low tumors. In particular, claudin-low tumors also highly express markers associated with epithelial-mesenchymal transition (EMT), such as vimentin and Twist.
In another recent study from our own group [6] , we found a gene signature pattern of TICs to be exhibited mainly in these claudin-low tumors. Figure 1 gives a schematic overview of this study's approach, examining human breast cancer using a gene "signature" of TICs (which consists of both a set of genes and the direction, "up" or "down," in which each gene changes). By gene expression profiling both FACS-sorted CD44 + /CD24
-/low cells and cancer-derived mammospheres, we defined an expression signature pattern of TICs. We then used this signature as a "probe" against expression datasets of whole tumor specimens from breast cancer patients, in order to score each tumor on the basis of whether its expression patterns are similar to that of the TICs. Tumors that score highly (which we denote by a high "R-value") tend to have high expression of the genes that are also high in TICs and low expression of the genes low in TICs.
In our study, breast tumors of the claudin-low molecular subtype, as represented in the Herschowitz study [17] , showed a clear and unambiguous association with the tumorigenic signature (results re-presented in Fig. 2a , left panel); all 13 of the claudin-low tumors had highly significant R-values, not seen in any tumors from the other subtypes. Furthermore, claudin-low tumors also showed low mRNA expression of CD24 and high mRNA expression of CD44, consistent with the notion that these tumors are enriched for CD44 + /CD24 -/low cells (i.e. TICs). Another important finding in our gene signature study was that our signature showed greater manifestation in primary cancers not only after chemotherapy, but also with endocrine therapy (i.e. letrozole), as compared to pre-treatment tumors (results re-presented in Fig. 2a , right panel); this finding complemented the result of our earlier study that tumors after chemotherapy had higher percentages of TICs, thereby further strengthening the "dandelion hypothesis." This enrichment of TICs after therapy appears to occur independently of molecular subtype, as for the example the letrozole-treated patients in our study presumably had tumors of the ER+/luminal subtype. While by a clinical definition, the post-endocrine therapy tumors may still express enough ER to remain ER+, the mRNA expression of ER was significantly lower post-treatment, according to our profiling data, which may reflect in part a greater enrichment for ER-TICs.
In addition to claudin-low tumors, one other rare subtype of breast cancer, metaplastic tumors, was recently found to share molecular similarities with TICs. Metaplastic breast cancers are aggressive, chemoresistant tumors characterized by mesenchymal/sarcomatoid and/or squamous metaplasia of malignant breast epithelium. In a recent study from Hennessey et al. [18] , a set of 28 metaplastic tumors were transcriptionally profiled and probed using our own TIC gene signature. As with the claudin-low tumors, most of the metaplastic tumors showed enrichment for EMT markers and high similarity to our TIC gene expression patterns. Metaplastic tumors also showed a high frequency of mutation, amplification, and activation of PI3K/AKT pathway components. Altogether, these results suggest that metaplastic and claudin-low tumors may arise from more -/low cells) and non-TICs (e.g. CD24
+ and CD44 -/CD24 -cells) are both profiled for gene expression, in order to define differentially expressed genes (i.e. a TIC gene "signature"). The TIC signature (which consists of one set of genes high and another set of genes low in TICs) is then used to score each of a panel of breast cancers on the basis of their gene expression patterns (e.g. high similarity score with the signature indicates that many of the TIC high genes are high in the given breast tumor, while many of the TIC low genes are low).
immature precursor cells than other breast cancers, though there were also molecular differences found between these two tumor types (for example, unlike metaplastic tumors, claudin-low tumors did not show mutations in PIK3CA, and a direct comparison between claudin-low and metaplastic transcriptomes shows widespread differences in gene expression), suggesting they are distinct from each other while sharing many similarities.
Gene Signatures of TICs
As demonstrated by recent studies, molecular profiling of TICs can provide insight into the processes and pathways underlying tumorigenesis. In our own study defining a gene transcription "signature" of TICs (i.e. the "Creighton et al." signature) [6] compare them to each other, to see if there are commonalities between them. When we compare the gene lists from our TIC signature with both the Liu and Shipitsin signatures, we find only a fraction of genes overlapping between the results of the different studies; however, this result is actually quite typical of gene expression metaanalysis studies, as any gene signature will likely have its share of false negatives (i.e. genes that are biologically important but which miss a given statistical cutoff). Another way to compare different TIC gene signatures is to see if each yields similar associations with human breast tumor subsets. In this review, we have therefore evaluated both signatures from Liu et al. and Shipitsin et al. for their association with the claudin-low intrinsic subtype and with letrozole post-treated versus pre-treated tumors. As we observed using our own TIC signature, the Shipitsin signature distinguishes the claudin-low subtype from the other intrinsic subtypes and was more manifest in the post letrozole-treated tumors (Fig. 2b) ; the Liu signature, on the other hand, shows no such patterns, and appears to associate more with the ER-negative intrinsic subtypes (including basal and ERBB2+) than with claudin-low subtype in particular (Fig. 2c) . Do these signatures of TICs have any prognostic ability? The Liu signature was previously found to be associated with poorer patient outcome on the basis of the expression profiles of the bulk primary tumors [19] . We examined whether our signature and the Shipitsin signature were similarly prognostic. When we examined the breast tumor expression profile dataset from van de Vijver et al. [21] , the dataset used in the Liu study, neither our signature nor the Shipitsin signature showed prognostic ability, though we were able to recapitulate the Liu results using their gene sets (Fig. 3) . These results appear to be in line with those of the Shipitsin study [20] , where they could identify subsets of genes in their signature that could be correlated with outcome, but were unable to show that their signature as a whole was prognostic. This lack of significance could perhaps be attributed to the low numbers of patients with claudin-low subtype tumors in the van de Vijver data set, as previously noted [22] . Furthermore, the TICs containing the claudin-low signature may represent only a very small subpopulation in most other breast cancer subtypes. Recent studies characterizing gene expression in stem cells from the normal human breast have demonstrated a similarity with the claudin-low signature [23] ; thus, if the claudin-low signature represents only a subpopulation of cells, we could reason that this signature might not be prognostic. One caveat to the Liu et al. analysis is that because tumor cells were compared to normal cells the signature is likely enriched for proliferation genes which may have a large affect on its predictive ability. In conclusion, it may be that a TIC gene signature is not prognostic in bulk tumors, though more studies may be needed; in particular, larger tumor datasets with a larger number of claudin-low tumors may be considered.
Epithelial-Mesenchymal Transition (EMT) in TICs
EMT is a multi-step process in which cells acquire molecular alterations that facilitate dysfunctional cell-cell adhesive interactions, loss of cell-cell junctions, and reorganization of the cytoskeleton, all of which result in the loss of apical polarity and the acquisition of a more spindle-shaped morphology [24] [25] [26] [27] [28] [29] . These processes are ultimately thought to promote cancer cell progression through the basement membrane and invasion into the surrounding microenvironment. However, unlike the classical EMT known to occur in embryonic development, which represents a relatively permanent change in cell identity and fate, the EMT observed in tumors might be better defined as a "transient mesenchymal appearance" or "transient mesenchymal conversion", since the EMT markers and phenotype are often not apparent in distant metastases. The mechanisms underlying the expression of these EMT markers are not well established, but may in part include epigenetic alterations in the TGFß pathway [20] .
Several recent studies provide support for the presence of EMT markers in invasive breast cancer, especially in the invasion-metastases cascade [30, 31] . By loss of heterozygosity (LOH) studies comparing the epithelial and stromal components of invasive breast cancers, EMT was found to be a rare occurrence in bulk primary tumors [32] . EMT has been described to play a role in the invasion-metastases cascade in some invasive cancers. Overexpression of a microRNA, miR-10b, was found to both be induced by the EMT transcription factor, Twist, and to inhibit the translation of the HoxD10 homeobox gene, resulting in increased expression of the prometastatic gene product RHOC, thereby favoring cancer cell invasion and migration [30] . More recently, both normal and breast cancer stem cells also have been shown to express low levels of the miR-200 family of microRNAs [33] , which are known to negatively regulate transcription factors Zeb1 and Zeb2 and to promote EMT. A double negative feedback pathway involving TGFß, Zeb1, and Zeb2, as well as the miR-200 family members, has been shown to regulate EMT. Furthermore, disruption of this inhibitory pathway, perhaps regulated by local paracrine TGFß signaling from the microenvironment, may be responsible for the reciprocal MET [34, 35] . Also of interest is the recent observation that the Akt pathway and specifically Akt2 also may negatively regulate miR-200 family expression, and that Akt1 may antagonize the inhibitory effect of Akt2 [36] .
Our own studies have suggested a role for EMT in TICs. The association that we found between breast cancer TICs and the mesenchymal claudin-low subtype on the basis of gene expression patterns, suggested that pathways of EMT may be involved. When we examined known markers of EMT in our expression data, we found that a number of these markers were elevated (FN1, VIM, FOXC2, MMP2 and MMP3) or diminished (CDH1 and DSP) at the RNA level, as anticipated in the cancer mammospheres. CD44 + / CD24 -/low flow-sorted cells also showed elevated VIM and decreased CDH1 and DSP. We next examined the expression of mesenchymal genes VIM and MMP2 in paired letrozole-treated breast cancer specimens and confirmed higher expression of both of these in tumors after treatment versus before treatment, with IHC studies indicating that the increase was from the epithelial cancer cells undergoing EMT.
Just prior to our study described above, Mani et al. [37] , starting from a completely different in vitro based cell line perspective, reported that the induction of EMT in immortalized human mammary epithelial cells, by ectopic expression of either the Twist or Snail transcription factors. Induction of EMT resulted in the acquisition of mesenchymal traits, an increased ability to form mammospheres, and in the expression of stem cell and TIC markers (namely, CD44 + /CD24 -/low ), suggesting that there may be a direct link between EMT and the gain of epithelial stem cell or TIC properties. In this regard, one of the genes, FOXC2, identified in our own mammosphere "tumorigenic" signature was also induced in cells undergoing EMT in vitro, and has been suggested to play a key role in orchestrating the mesenchymal component of the EMT program [38] . The Mani et al. study nicely complemented our own observations which were based on human specimens. Altogether, these studies have led to the hypothesis that resistance to conventional therapies may be associated, at least in part, with an EMT-like gene expression program.
Targeting TICs in Human Breast Cancers
The cancer stem cell hypothesis has fundamental clinical implications, as the current development of cancer therapeutics is largely based on identifying agents which have the ability to cause bulk tumor regression in animal models or in clinical trials. Since TICs comprise only a small percent of the tumor bulk, focus on tumor regression may have produced agents which are able to kill actively cycling or fully differentiated cells while sparing the tumor stem cell population. This provides an explanation for the clinical observation that tumor regression may not correlate with patient survival. As TICs in breast cancer appear more resistant to chemotherapy and radiation therapy, more effective therapies will thus require the selective targeting of this crucial cell population. The elucidation of molecular pathways which regulate TIC self-renewal and survival provides potential therapeutic targets. To this end, Gupta et al. [39] recently implemented a chemical screen and discovered compounds showing selective toxicity for breast TICs, including salinomycin.
A number of developmental signaling pathways have been shown to play a role in mammary carcinogenesis and stem cell biology including Notch, PI3-AKT, Wnt, Hedgehog and p53. Notch, along with a number of other pathways including TGFß, has been found to contribute to EMT [40] . Approximately 50% of human breast cancers show defects in Notch signaling, largely mediated by reduced expression of the Notch inhibitor, NUMB [41] [42] [43] [44] [45] . Evidence support that Notch plays a key role, in the regulation of asymmetric cell fate decisions in human mammary stem cells [41] [42] [43] [44] [45] . Notch activation requires the action of the proteolytic enzyme gamma secretase. Of the canonical pathways from Ingenuity Pathway Analysis represented by our own TIC gene signature, Notch was one of the top upregulated pathways. Recent evidence also suggest that both hereditary breast cancers in BRCA1 carriers [46] , as well as sporadic breast cancers driven by HER2 amplification, may result from dysregulation of stem cell self-renewal pathways. Our preliminary data from a neoadjuvant lapatinib study suggests that breast cancer stem cells are relatively resistant the chemotherapy, but are affected by the EGFR/HER2 inhibitor lapatinib [5] . A molecular mechanism for these clinical results was provided by the recent finding that HER2 stimulates the selfrenewal of breast cancer stem cells through the PI3K-AKT pathway [47] .
Even though the claudin-low tumors only represent less than 5% of breast cancers, an understanding of their properties should provide important new insights into cells that are intrinsically resistant to conventional treatments, in the majority of breast cancers. Since the Herschkowitz study identified within the syngeneic p53 mouse breast cancer model tumors which exhibit the claudin-low molecular phenotype [17] , we are now well positioned to ask critical questions concerning the mechanisms involved in intrinsic therapeutic resistance, using this in vivo model system in hand to empirically determine how to attack TICs therapeutically. In principle, it should then be eventually possible to translate these approaches into the clinic in the neoadjuvant and metastatic setting.
Conclusions
In this review, we have discussed recent studies suggesting that EMT is a critical process underlying the subpopulation of breast cancer cells that is responsible for tumor initiation and for regenerating the tumor after initial bulk tumor regression following therapy. Additional studies will be necessary in order to better establish and to increase our understanding of the role of EMT in TICs. For example, with regards to the claudin-low breast tumor molecular subtype, it remains to be established that these tumors do in fact have a higher proportion of TICs (our group is currently working on providing support for this hypothesis). We also might expect that claudin-lows to be more aggressive and to have a worse outcome as compared to other tumor types such as luminal A. As claudin-low tumors appear to be rather rare, examining both of the above questions would likely involve studies of larger breast tumor cohorts (perhaps on the order of 500-1,000 samples), in order for there to be sufficient numbers of claudin-low tumors for meaningful statistics. It may be that a high percentage of TICs within a given bulk tumor that would be predictive of poor patient outcome, though more data are needed to prove this. Furthermore, additional functional studies (e.g. using both mammosphere and limiting dilution transplantation assays) could explore the impact of targeting various mediators of EMT in TICs. In addition to the pathways described above, the role of EMTassociated microRNAs in TIC behavior should be further examined. In conclusion, the link between EMT and TICs is exciting and will no doubt be a hot topic for future studies.
